Treatment with NMDA receptor antagonists

Overstimulation of the NMDA receptors by glutamate is implicated in neurodegenerative disorders, including Alzheimer’s disease (AD) ¹

The NMDA receptor antagonist memantine is approved for the treatment of moderate/severe AD alone or in combination with cholinesterase inhibitors^2-4

Memantine has been shown to reduce clinical deterioration in moderate/severe AD¹

Furthermore, treatment with memantine has been shown to reduce symptoms such as agitation, aggression, irritability,and appetite disturbances⁵

Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.